GALT GALECTIN THERAPEUTICS INC Insider Trading

Director Eldred Kary purchases 300 shares of GALT at $2.70; stock down 58.2% from 52-week high amid unprofitable operations.

Eldred Kary, a Director at Galectin Therapeutics, purchased 300 shares at $2.70 on 2026-02-06, increasing his holdings to 65.7K shares. The purchase occurred as GALT trades at -58.2% from its 52-week high of $6.51 and has declined 50.6% over the past 90 days. Notably, Kary's prior trades at GALT show mixed timing results: two recent buys in late December 2025 are down 5.4% in the 30-day window, while earlier 2025 and 2024 purchases demonstrated stronger outcomes (70.6% and 101.2% 90-day gains respectively). The company remains unprofitable with a net loss of $8.2M in its most recent fiscal year, creating fundamental headwinds that complicate interpretation of director buying activity as a confidence signal.

GALT director Eldred Kary buys 700 shares at $3.73 on 12/23; stock down 38.7% YTD, but prior GALT buys showed +70.6% and +101.2% 90-day returns.

Eldred Kary purchased 700 shares of GALECTIN THERAPEUTICS INC at $3.73, adding 1.1% to his 64.7K share position at a time when the stock trades at $3.99, down 25.4% over the prior 30 days and 38.7% from its 52-week high of $6.51. The company reported net income of $-8,200,000.00 in its most recent fiscal year. However, Kary's prior transaction history at GALT shows a consistent pattern of well-timed entry points: his four prior measurable buys at this ticker yielded +33.3%, +50.0%, +6.9%, and -26.8% returns at 30 days, with 90-day returns of +70.6%, +101.2%, -52.7%, and +63.6% respectively—3 of the 4 prior buys ultimately proved well-timed at the 90-day horizon. This latest acquisition occurs in the context of pronounced recent weakness and appears aligned with his historical pattern of accumulating during or after declines.

Director Freeman bought 5,500 GALT shares at $3.55; stock down 38.7% from 52-week high, company unprofitable.

Director Kevin D Freeman purchased 5,500 shares at $3.55 on 2025-12-23, increasing his holdings by 11.1% to 55,269 shares. The buy occurs in an unfavorable price environment: the stock is currently $3.99, down 38.7% from its 52-week high of $6.51 and down 25.4% over the prior 30 days. Freeman's same-ticker history at GALT shows mixed predictive power, with 2 of 5 prior buys achieving positive 90-day returns, but the company posted a net loss of $8,184,000.00 in its most recent full fiscal year. The timing and valuation context do not clearly signal insider conviction about near-term recovery, particularly given recent downward price momentum and ongoing unprofitability.

Director Eldred Kary purchases 700 GALT shares at $3.73; stock down 25.4% in 30 days amid -$8.2M net income.

Eldred Kary, a director, purchased 700 shares of Galectin Therapeutics at $3.73 on 2025-12-23, increasing his holdings to 65.4K shares. The timing occurs within a steep drawdown: the stock has declined 25.4% over 30 days and 16.0% over 90 days, trading 38.7% below its 52-week high of $6.51. Notably, his prior four completed GALT trades show a 3-of-4 success rate at the 90-day mark (three generated positive returns of +33.3%, +50.0%, and +63.6%, while one underperformed at -52.7%), establishing a pattern of opportunistic entry timing at this ticker. However, the company remains unprofitable, with a full-year net income of -$8.2M, which frames this purchase as occurring during fundamental stress rather than near a business inflection point.

Director Shlevin sold 175,790 shares (94.0% of holdings) for $1.1M across 8 transactions on 2025-12-08 to 2025-12-09

Harold Shlevin, a director at Galectin Therapeutics, executed 8 separate sales totaling 175,790 shares for $1,055,311.14 at an average price of $6.00 per share, reducing his stake from 186,996 shares to 11,206 shares—a 94.0% reduction in holdings. The sales occurred at prices ranging from $5.95 to $6.27 per share, near the 52-week high of $6.30 and $0.81 above the current price of $5.49. The company is unprofitable with a net loss of $8,184,000.00 over the most recent full fiscal year, and Shlevin's prior buy activity at this ticker (1 prior trade in December 2024) showed positive 90-day returns of 31.0%, suggesting his historical timing at GALT has been favorable. The near-complete liquidation of a director's position during an unprofitable period, at prices near 52-week highs, warrants investor attention to underlying business dynamics and management confidence signals.

CMO Jamil Khurram sold 121,117 shares ($662.5K) in 4 separate transactions at $5.47; 96.4% of holdings liquidated

Jamil Khurram, Chief Medical Officer, executed 4 separate sales totaling 121,117 shares for $662,509.99, reducing his holdings from 125,596 shares to 4,479 shares—a near-complete liquidation representing -96.4% of pre-transaction holdings. The transaction occurs as GALECTIN THERAPEUTICS reports a negative net income of $-8,184,000.00 and faces ongoing unprofitability. The magnitude and concentration of this sale by a senior medical officer warrants investor attention, particularly in a loss-making biotech context where insider equity stakes typically carry significant informational weight.

Director Eldred Kary bought 1,000 shares of GALT at $2.92 on 2025-07-21; director now holds 64,682 shares. Strong recent momentum (+113.4% over 90 days) vs unprofitable fundamentals.

Director Eldred Kary purchased 1,000 shares at $2.92, adding to a position that now totals 64,682 shares. His prior four transactions at Galectin Therapeutics show strong 90-day timing: three of the four measurable outcomes (2024-12-24, 2024-01-16, 2024-01-16) delivered positive 90-day returns of +101.2%, +119.0%, and +63.6% respectively, suggesting pattern recognition of entry points that preceded material gains. The current environment shows +113.4% upside over the past 90 days and +18.2% over the past 30 days, positioning this purchase well within a momentum phase. However, the company remains unprofitable with net income of $-9.6M, creating tension between insider accumulation and deteriorating fundamentals—a dynamic warranting deeper review of what operational or clinical developments may underpin the director's conviction at $2.92.

Director Kevin Freeman bought 5,000 shares of GALT at $2.90; stock now at $2.80, down 14.9% in 30 days from purchase.

Freeman purchased 5,000 shares at $2.90 on 2025-07-17, increasing his holdings from 44.8K to 49.8K shares (+11.2%), for a total outlay of $14.5K. The stock has declined to $2.80 current price, representing a -14.9% loss from his purchase price in just over a month. Across his prior 5 trades in GALT, Freeman's timing outcomes were mixed: 2 of 5 buys achieved positive 90-day returns (well-timed), while 3 underperformed, with 90-day declines ranging from -51.5% to -57.4%. The company remains unprofitable with a net loss of $-9.6M over its most recent full fiscal year, and the stock is trading 14.9% below its 52-week high of $3.29.

Director Shlevin bought 6,500 GALT shares at $1.16 on 12/30/24; stock down 55.4% in 30 days; 3 other insiders also bought in past 14 days

Director Harold Shlevin purchased 6,500 shares for $7,540.00 at $1.16, increasing his holdings by 74.7% to 15,206 shares—a material increase in his ownership position at Galectin Therapeutics. This transaction occurred as the stock trades 69.3% below its 52-week high and has declined 55.4% over the past 30 days, while the company reported a full fiscal year net income of $-11,220,000.00. The filing shows a cluster pattern with 3 other insiders purchasing within the same 14-day window, suggesting coordinated management confidence during a period of significant share-price weakness. The timing and scale of these concurrent insider purchases—particularly the substantial relative increase in Shlevin's stake—merit close attention given the company's unprofitable status and the magnitude of recent price deterioration.

Director Kevin D Freeman buys 10,000 GALT shares at $0.81; stock down -79.3% from 52-week high, company unprofitable.

Freeman, a director of Galectin Therapeutics, purchased 10,000 shares at $0.81 on 2024-12-24, increasing his holdings by 28.8% to 44.8K shares. The transaction occurred in a context of significant price deterioration: the stock is -79.3% from its 52-week high of $4.20 and has declined -68.6% over the prior 30 days. At the same ticker, Freeman has a mixed track record: 5 prior purchases show a 50% win rate at the 90-day mark, with outcomes ranging from +13.9% to -18.8%. The company is unprofitable, posting a net loss of $-11.2M over its most recent fiscal year. Notably, 2 other insiders also bought GALT within the past 14 days, suggesting alignment among multiple board/management members on valuation at current depressed levels.